Title: Pfizer/BioNTech COVID-19 vaccine shows 90.7% efficacy in trial in children

10/22/2021 08:36:16 AM GMT

By: AnalysisWatch

The Pfizer/BioNTech COVID-19 antibody showed 90.7% viability against Covid in a clinical preliminary study of youngsters 5 to 11 years of age, the U.S. drugmaker said on Friday.

Sixteen kids in the preliminary who had gotten a fake treatment got COVID-19, contrasted and 3 who were immunized, Pfizer (NYSE:PFE) said in preparation archives submitted to the U.S. Food and Drug Administration.

Since the antibody was given to more than twice as many children in the 2,268-person preliminary study as the fake treatment, the viability rate was greater than 90%.

Pfizer's clinical preliminary in those 5 to 11 years of age was not principally intended to quantify viability against the infection. Overall, it compared the number of killing antibodies induced by immunization in children to the reaction of more established beneficiaries in their grown-up preliminary.

Outside guides to the FDA are booked to meet on Tuesday to decide on whether to suggest that the organization approve the antibody for that age bunch.

The Pfizer/BioNTech immunization, as of now, has U.S. administrative approval for individuals who are somewhere around 12 years of age, incorporating full FDA endorsement in August for those 16 and up.

Around 190 million individuals in the United States are completely inoculated, including in excess of 11 million who are 12 to 17 years of age that have gotten the Pfizer antibody.

In the event that the FDA approves the immunization for kids 5 to 11 years of age, a gathering of guides to the U.S. Places for Disease Control and Prevention will meet on Nov. 2 and 3 to make suggestions to the organization on how the shots ought to be directed. Most states trust that the CDC will approve suggestions for immunizations before they start regulating shots.